Open Access

Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer

  • Authors:
    • Ping Chen
    • Qi Qian
    • Zhiyuan Zhu
    • Xiaohui Shen
    • Shenling Yu
    • Zhenghong Yu
    • Rui Sun
    • Yiping Li
    • Didi Guo
    • Hong Fan
  • View Affiliations

  • Published online on: June 5, 2020     https://doi.org/10.3892/ol.2020.11694
  • Pages: 1734-1742
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Di‑methylated lysine 9 of histone H3 (H3K9me2), regulated by histone methyltransferases, is involved in the epigenetic regulation of tumor‑associated genes. The present study aimed to evaluate whether the H3K9me2 methylation level is associated with the expression level of euchromatic histone lysine methyltransferase 2 (EHMT2) in the prognosis of gastric cancer (GC). H3K9me2 methylation level and EHMT2 expression level were detected by immunohistochemistry in 118 GC samples. The clinicopathological significance of H3K9me2 and EHMT2 in patients with GC was assessed using a paired Student's t‑test, χ2 test, Kaplan‑Meier analysis with a log‑rank test and Cox's proportional hazard analysis. Strong positive immunostaining of H3K9me2 and EHMT2 was observed in cancerous tissues compared with adjacent non‑cancerous tissues. Positive immunostaining of EHMT2 and H3K9me2 was associated with lymph node metastasis, pathological grade and tumor‑node‑metastasis stage. H3K9me2 expression level was increased in tumor tissue and associated with worse specific‑disease and disease‑free survival time. In addition, EHMT2 protein expression levels were associated with the expression levels of H3K9me2. Low expression levels of H3K9me2 and EHMT2 predicted a better prognosis of patients with GC. The survival time of patients with a high expression of H3K9me2 and/or EHMT2 was significantly shorter compared with that of the patients with a low expression of H3K9me2 and/or EHMT2. In conclusion, an overexpression pattern of H3K9me2 and/or EHMT2 may be associated with clinicopathological features of GC and may be predictor markers of progression and prognosis in patients with GC, in addition to putative therapeutic targets.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Chen, P., Qian, Q., Zhu, Z., Shen, X., Yu, S., Yu, Z. ... Fan, H. (2020). Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer . Oncology Letters, 20, 1734-1742. https://doi.org/10.3892/ol.2020.11694
MLA
Chen, P., Qian, Q., Zhu, Z., Shen, X., Yu, S., Yu, Z., Sun, R., Li, Y., Guo, D., Fan, H."Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer ". Oncology Letters 20.2 (2020): 1734-1742.
Chicago
Chen, P., Qian, Q., Zhu, Z., Shen, X., Yu, S., Yu, Z., Sun, R., Li, Y., Guo, D., Fan, H."Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer ". Oncology Letters 20, no. 2 (2020): 1734-1742. https://doi.org/10.3892/ol.2020.11694